PhRMA, BIO, GPhA Join Forces to Oppose California Drug Disposal Measure


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 07-14-2014 14:31

  
Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), and the Generic Pharmaceutical Association (GPhA), participated in oral arguments in the US Court of Appeals for the Ninth Circuit, in appeal of the district court ruling in favor of Alameda County's Safe Drug Disposal ordinance, which requires pharmaceutical companies to design, fund, and operate a collection program in the county for unused medicines in the home.

"Today's oral arguments offered an important opportunity to educate stakeholders within Alameda County and all of California about the unnecessary and burdensome impacts that will result if this proposed take back program is allowed to stand," said BIO and GPhA in a joint statement. "This proposed approach is impractical, inefficient, and reflects an attempt on the part of the county to directly, significantly, and unconstitutionally regulate companies whose connection with Alameda is nothing more than having introduced federally approved products into interstate commerce. We support safe disposal of medications, and today consumers have several options available to them that are considered safe and effective by both the FDA and DEA [Drug Enforcement Agency]. These methods include various means of convenient in-home disposal, as well as take back days organized by local and national law enforcement agencies, among others."

In the statement, the associations said: "While existing programs like the DEA National Take-Back Day can offer benefits to communities, creating mandates for dispersed take-back sites that place funding and sole responsibility upon the manufacturers of medicine is not only unfair cost-shifting, but may well increase the risks associated with unused medicines. We remain confident in our legal position, and look forward to continued collaboration with local leadership to address patient safety and disposal concerns."

Source: BIO and GPhA

 

0 comments
30 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink